Biologic Makers Thwart Generics: Winning Stocks [Pfizer Inc., Amgen, Inc … – Seeking Alpha
|
Biologic Makers Thwart Generics: Winning Stocks [Pfizer Inc., Amgen, Inc …
Seeking Alpha Hospira (HSP) and Teva halted late-stage development of follow-on versions of Roche AG’s monoclonal antibody Rituxan (rituximab) — $3.1 billion in domestic sales, trailing 12-months – due to rising R&D costs. Similar to strategies used to delay entry … |
